Wafika Zarzour, W. Habbal, Alaa Oraige, A. Ganama, Raghad Serri
{"title":"估计在叙利亚阿拉伯国际大学接触SARS-CoV-2:大流行一年后的快照","authors":"Wafika Zarzour, W. Habbal, Alaa Oraige, A. Ganama, Raghad Serri","doi":"10.21608/bfsa.2023.189767.1659","DOIUrl":null,"url":null,"abstract":"Background: After a year of pandemic in Syria, how prevalent the seropositivity is, and how far we are from herd immunity is a raised question. Aim: Our study aimed to estimate the overall exposure to SARS-COV-2 depending on the COVID-19-specific symptoms as well as the seroprevalence of anti-SARS-CoV-2 IgG antibodies among students and staff at the Arab International University (AIU) in Syria. Methods: All AIU students and staff were invited to voluntarily participate in the study by filling out and submitting an anonymous web-based survey. Responses were evaluated then asymptomatic and pauci-symptomatic respondents were notified of a phlebotomy appointment. Anti-SARS-CoV-2 IgG antibodies were analyzed by ELISA. Results: One third (122 of 381; 32%) of respondents were asymptomatic. The remaining respondents reported COVID-19-specific symptoms (177 of 381; 46.5%), mainly anosmia and/or ageusia (132 of 177; 74.5%), or nonspecific symptoms (82 of 381; 21.5%). Frequencies of symptoms onset showed a strong, positive correlation with the incidence of confirmed SARS-CoV-2 RNA-positive cases reported by the Ministry of Health in Syria. Anti-SARS-CoV-2 IgG antibodies were similarly detected in both symptomatic (21 of 33; 63.6%) and asymptomatic (39 of 61; 63.9%) individuals (P=.97). Conclusions: After a year of pandemic, a 69% exposure to SARS-CoV-2 is roughly estimated amongst asymptomatic and pauci-symptomatic individuals. Further post-vaccination assessment of seroprevalence against SARS-CoV-2 in future large-scale studies might provide a more complete picture of the SARS-CoV-2 epidemic in Syria.","PeriodicalId":345040,"journal":{"name":"Bulletin of Pharmaceutical Sciences. Assiut","volume":"355 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Estimating exposure to SARS-CoV-2 at the Arab International University, Syria: a snapshot after a year of pandemic\",\"authors\":\"Wafika Zarzour, W. Habbal, Alaa Oraige, A. Ganama, Raghad Serri\",\"doi\":\"10.21608/bfsa.2023.189767.1659\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: After a year of pandemic in Syria, how prevalent the seropositivity is, and how far we are from herd immunity is a raised question. Aim: Our study aimed to estimate the overall exposure to SARS-COV-2 depending on the COVID-19-specific symptoms as well as the seroprevalence of anti-SARS-CoV-2 IgG antibodies among students and staff at the Arab International University (AIU) in Syria. Methods: All AIU students and staff were invited to voluntarily participate in the study by filling out and submitting an anonymous web-based survey. Responses were evaluated then asymptomatic and pauci-symptomatic respondents were notified of a phlebotomy appointment. Anti-SARS-CoV-2 IgG antibodies were analyzed by ELISA. Results: One third (122 of 381; 32%) of respondents were asymptomatic. The remaining respondents reported COVID-19-specific symptoms (177 of 381; 46.5%), mainly anosmia and/or ageusia (132 of 177; 74.5%), or nonspecific symptoms (82 of 381; 21.5%). Frequencies of symptoms onset showed a strong, positive correlation with the incidence of confirmed SARS-CoV-2 RNA-positive cases reported by the Ministry of Health in Syria. Anti-SARS-CoV-2 IgG antibodies were similarly detected in both symptomatic (21 of 33; 63.6%) and asymptomatic (39 of 61; 63.9%) individuals (P=.97). Conclusions: After a year of pandemic, a 69% exposure to SARS-CoV-2 is roughly estimated amongst asymptomatic and pauci-symptomatic individuals. Further post-vaccination assessment of seroprevalence against SARS-CoV-2 in future large-scale studies might provide a more complete picture of the SARS-CoV-2 epidemic in Syria.\",\"PeriodicalId\":345040,\"journal\":{\"name\":\"Bulletin of Pharmaceutical Sciences. Assiut\",\"volume\":\"355 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Pharmaceutical Sciences. Assiut\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/bfsa.2023.189767.1659\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Pharmaceutical Sciences. Assiut","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/bfsa.2023.189767.1659","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Estimating exposure to SARS-CoV-2 at the Arab International University, Syria: a snapshot after a year of pandemic
Background: After a year of pandemic in Syria, how prevalent the seropositivity is, and how far we are from herd immunity is a raised question. Aim: Our study aimed to estimate the overall exposure to SARS-COV-2 depending on the COVID-19-specific symptoms as well as the seroprevalence of anti-SARS-CoV-2 IgG antibodies among students and staff at the Arab International University (AIU) in Syria. Methods: All AIU students and staff were invited to voluntarily participate in the study by filling out and submitting an anonymous web-based survey. Responses were evaluated then asymptomatic and pauci-symptomatic respondents were notified of a phlebotomy appointment. Anti-SARS-CoV-2 IgG antibodies were analyzed by ELISA. Results: One third (122 of 381; 32%) of respondents were asymptomatic. The remaining respondents reported COVID-19-specific symptoms (177 of 381; 46.5%), mainly anosmia and/or ageusia (132 of 177; 74.5%), or nonspecific symptoms (82 of 381; 21.5%). Frequencies of symptoms onset showed a strong, positive correlation with the incidence of confirmed SARS-CoV-2 RNA-positive cases reported by the Ministry of Health in Syria. Anti-SARS-CoV-2 IgG antibodies were similarly detected in both symptomatic (21 of 33; 63.6%) and asymptomatic (39 of 61; 63.9%) individuals (P=.97). Conclusions: After a year of pandemic, a 69% exposure to SARS-CoV-2 is roughly estimated amongst asymptomatic and pauci-symptomatic individuals. Further post-vaccination assessment of seroprevalence against SARS-CoV-2 in future large-scale studies might provide a more complete picture of the SARS-CoV-2 epidemic in Syria.